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SUMMARY  
This article summarizes the results of several of our studies on medication safety in pregnancy based on the 
Norwegian Mother and Child Cohort Study (MoBa). Medications investigated include antidepressants, NSAIDs, 
codeine, triptans, paracetamol and certain herbals. A major advantage of these studies is that MoBa has infor-
mation on prescribed medications, over-the-counter medications and herbal medications. Moreover, MoBa 
enables the possibility of including a disease comparison group, and long-term follow-up into childhood. The 
size of MoBa enables designs like the sibling-design, which offers important advantages over studies comparing 
unrelated individuals. The possibility of linking MoBa to nationwide registries like the NorPD and the National 
Patient Registry enables validation of medication exposures and childhood diagnosis. Pharmacoepidemiological 
studies are vital to our understanding of the safety of medications in pregnancy, but great care must be taken in 
the analysis and interpretation of observational data to avoid problems of confounding and bias. 
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Because drugs may cause injury to the unborn child, 
we need to know which drugs are safe to use during 
pregnancy and which are not. This lesson was learned 
in the 1960s and 1970s when almost 10,000 children 
were born with malformed extremities after exposure 
to thalidomide during pregnancy. Today, up to eight 
out of ten women use one or more medications during 
pregnancy, many of them without sound information 
about safety in pregnancy (1). Almost 6 out of 10 
women in Norway filled at least one prescription medi-
cation during pregnancy according to the Norwegian 
Prescription Registry (NorPD) (2). Though caution in 
the use of psychiatric medication is recommended, stu-
dies show a marked increase in use of antidepressants 
in pregnancy in the last ten years, with the most recent 
prevalence of use ranging from to 3-4% in Europe and 
Australia up to 8.3% in North America (1). Over half 
of all pregnant women use analgesics during pregnan-
cy, most commonly over-the-counter paracetamol (1,3). 
 Avoiding all drugs in pregnancy is unrealistic, and 
may even be dangerous. Untreated severe mental ill-
nesses, epilepsy, diabetes, and infections in pregnancy 
are conditions in which the underlying illness itself 
may be harmful to the fetus, and thus require treat-
ment. On the other hand, superfluous use of drugs may 
also occur during pregnancy and have potential nega-
tive consequences to the health of the woman and the 
unborn child. 
 In the general population, our knowledge of medi-
cation safety is based on clinical trials. However, preg-
nant women are routinely excluded from these studies 
due to uncertainty about the effects of medication on 
fetal development. Therefore, in practice, pharmaco-
epidemiological studies provide the best way of 
evaluating whether an exposure during pregnancy has 
adverse effects on the developing fetus (4). 
AIM 
 
The aim of this article is to summarize the results of 
several of our studies on medication safety in preg-
nancy based on The Norwegian Mother and Child Co-
hort Study (MoBa). Moreover, we will discuss some of 
the challenges in interpreting results from pharmaco-
epidemiological studies and criteria for causation in 
teratology. 
 
OVERVIEW OF MOBA “MEDICATION SAFETY 
IN PREGNANCY” SUB-STUDIES 
 
Antidepressants  
Two of our MoBa sub-studies focused on the safety of 
antidepressants, which is probably the most debated 
medication group with respect to safety in pregnancy. 
Results from previous medication safety studies have 
been conflicting (5). As many women will have to con-
tinue their antidepressant therapy during pregnancy, it 
is essential to establish their safety and determine 
whether there are differences in risk between different 
groups of antidepressants. Psychiatric illnesses are 
common among women in reproductive age, affecting 
up to 20% of all pregnant women (6), and untreated 
severe mental illnesses may in itself be harmful to the 
fetus (5). 
 In the first study, 699 of the 63,395 MoBa women 
(1.1%) reported using antidepressants during preg-
nancy, most frequently SSRIs (0.9%) (7). Exposure to 
SSRIs during the first trimester was not associated with 
increased risk of overall congenital malformations (ad-
justed odds ratio (OR) 1.22; 95% confidence interval 
(CI) 0.81–1.84) or cardiovascular malformations (ad-
justed OR 1.51; 95% CI 0.67–3.43). Exposure to anti-
depressants during pregnancy was not associated with 
increased risk of low birth weight (adjusted OR 0.62; 
95% CI 0.33–1.16). 
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In crude analyses, exposure to antidepressants was 
associated with an increased risk of preterm birth 
(crude OR 1.46; 95% CI 1.04–2.04); however, after 
adjustment for depression and socio-demographic 
characteristics no increased risk of preterm birth was 
identified (adjusted OR 1.21; 95% CI 0.87–1.69). In 
fact, having symptoms of depression in pregnancy was 
in itself significantly associated with preterm birth 
(adjusted OR 1.13; 95% CI 1.03–1.25). 
 These findings are reassuring with respect to anti-
depressant use during pregnancy and illustrate the 
importance of adjustment for the underlying illness in 
pharmacoepidemiological studies. Without adjust-
ments for level of maternal depression and various 
socio-demographic and lifestyle factors, antidepressant 
use during pregnancy would wrongly have been 
associated with an increased risk of preterm birth. 
 The background for the second study was lack of 
knowledge about risks of vaginal bleeding and post-
partum hemorrhage after use of antidepressants in preg-
nancy (8). An increase in the risk of gastrointestinal 
bleeding and bruising had been reported in non-
pregnant subjects after use of SSRI-antidepressants, 
possibly due to an effect on serotonin in blood 
platelets and thereby on hemostasis. Analyses were 
performed according to type of antidepressant, tri-
mester of exposure, amount of bleeding, number of 
bleeding episodes and timing of bleeding in preg-
nancy/post-partum. No increased risk of bleeding com-
plications was identified after use of antidepressants in 
pregnancy. However, the disease comparison group 
(non-medicated women with symptoms of depression) 
had a moderately increased risk of vaginal bleeding in 
early (adjusted OR 1.28; 95% CI 1.07–1.55) and mid-
pregnancy (adjusted OR 1.24; 95% CI 1.00–1.55). 
These women had more severe symptoms of depression 
than their medicated counterparts, suggesting a poten-
tial involvement of the underlying maternal depression 
in vaginal bleeding outcomes that should be explored 
in future studies. 
 
Analgesics  
We have published four articles on safety of analgesics 
based on data from the MoBa cohort, including two on 
NSAIDs (9,10), one on codeine (11) and one on trip-
tans (12). Based on animal and prior epidemiological 
studies indicating a possible link between COX-1 
inhibition and cardiac, midline and diaphragm defects 
(13), we wished to explore the association between 
exposure to NSAIDs in the first 12 weeks of gestation 
and these malformations. We found that despite being 
contraindicated in the first trimester, over 3000 women 
in MoBa (4.5%) reported to have used NSAIDs in 
early pregnancy (9). No significant increased risk of 
congenital heart defects or orofacial clefts was detec-
ted, although there was a non-significant increased risk 
of septal defects after exposure to multiple NSAIDs in 
the first 12 weeks of gestation (2 exposed cases; crude 
odds ratio 3.9, 95% CI 0.9–15.7) (9). Previously Ofori 
et al. reported a similar increased risk of septal defects 
after exposure to NSAID in the first trimester (21 
exposed cases; adjusted OR 3.3; 95% CI 1.9–6.0) (14). 
Consequently, this finding should be explored in future 
studies with sufficient power to assess the risk of 
septal defects after exposure to specific NSAID during 
the first trimester of pregnancy. 
 As a continuation of this study, we performed a 
second NSAID study including additional pregnancy 
outcomes like low birth weight, premature delivery, 
maternal hemorrhage and referral to a specialist for 
asthmatic symptoms in the child at 18 months (10). 
The last two outcomes were selected as NSAIDs inhi-
bit the blood clotting function of platelets by inhibiting 
prostaglandin synthesis, and may worsen symptoms of 
asthma in sensitive patients (13). 
 In total, 6511 (7.2%) reported using one or several 
of the NSAIDs, most commonly ibuprofen (n=5325, 
5.9%) (10). There was a borderline significant associa-
tion between ibuprofen use during the first trimester 
and structural heart defects in the 18-month-old child 
(1.5% vs. 1.2% among non-exposed controls, adjusted 
OR 1.2; 95% CI 1.0–1.6) (10). Second trimester expo-
sure to ibuprofen (adjusted OR 1.7; 95% CI 1.3–2.3) 
or diclophenac (adjusted OR 3.1; 95% CI 1.1–9.0) was 
significantly associated with low birth weight. More-
over, infants exposed to ibuprofen in the second tri-
mester (adjusted OR 1.5; 95% CI 1.2–1.9) or in the 
third trimester (adjusted OR 1.5; 95% CI 1.1–2.1) had 
an increased risk of having asthmatic symptoms at 18 
months of age compared to non-exposed infants. 
Finally, several of the NSAIDs were associated with 
an increased risk of vaginal bleeding and post-partum 
hemorrhage (10).  
 These results support current pharmacotherapeutic 
guidelines that contraindicate NSAIDs in the first and 
third trimester, and recommend caution with use in the 
second trimester of pregnancy (13). 
 For women in need of stronger analgesics than para-
cetamol or NSAIDs, the first line choice is codeine in 
a fixed combination with paracetamol (30 mg codeine 
+ paracetamol 400-500 mg). Leading literature sources 
on drug safety in pregnancy consider that sporadic use 
of codeine is safe in pregnancy (13,15), but surprising-
ly few studies have been conducted on codeine use in 
pregnancy in therapeutic doses in a population-based 
sample. In our MoBa sub-study, 1449 women (2.1%) 
used codeine during pregnancy (98% in a fixed combi-
nation of codeine/paracetamol), of whom 627 (0.9%) 
used it in the first trimester (11,16). No significant 
difference in the major congenital malformation rate 
was found between infants exposed to codeine in the 
first trimester (2.6%) and the unexposed group (3.0%) 
(adjusted OR 0.8; 95% CI 0.5–1.4) (11,16). Of note, 
codeine use was associated with both planned and 
acute caesarean delivery, probably due to the woman’s 
underlying pain condition. These results are reassuring 
with respect to congenital malformations. 
 Our interest in treatment of pain in pregnancy led us 
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to focus on a specific group of women often in need of 
analgesics, namely women with migraine. Migraine 
affects more than 15% of women, and although 
migraine symptoms will improve for many of them 
during pregnancy, pharmacotherapy is essential for 
some pregnant women (13). Untreated or inadequately 
managed severe migraine in itself may also present a 
risk to both the mother and child (13). 
 First, we characterized the MoBa population of 
migraineurs. Women using migraine pharmacotherapy 
during pregnancy were more likely to have several 
known migraine risk factors including poor sleep qual-
ity and high pre-gestational body mass index (17). They 
were also considerably more often on sick leave during 
pregnancy compared to women without migraine. 
 Secondly, we wished to investigate the safety of 
triptans, a widely used medication group against acute 
migraine attacks. Few previous studies had been con-
ducted on this class of medications, and consequently 
caution with use in pregnancy is recommended (18). In 
total, 1045 women in this MoBa sub-study (1.5%) 
used triptans during pregnancy (12,19). In addition, 805 
women (1.1%) used triptans prior to pregnancy, but 
not in pregnancy, and were included in the analyses as 
a disease comparison group. Use of triptans during the 
first trimester was not associated with any increased 
risk of major congenital malformations (3.5% among 
exposed vs. 2.9% in the population comparison group, 
adjusted OR 1.2; 95% CI 0.7–1.9). Interestingly, 
women in the migraine comparison group had an 
increased risk of stillbirth (adjusted OR 5.6; 95% CI 
1.3–23.7). This finding was based on only two exposed 
cases, and consequently should be explored in yet 
larger studies. 
 
Medication safety on neurodevelopmental outcomes  
While the majority of medication safety studies in preg-
nancy focus on immediate pregnancy outcomes, the 
long-term outcomes, although of equally paramount 
importance, have received limited attention. The bio-
logical plausibility of neurodevelopmental effects of in 
utero psychotropic exposure is related to their ability to 
pass the blood-placenta barrier (20) and their ability to 
bind to receptors in the developing fetus. 
 In our most recent study published we found that 
three year old children who had been exposed to 
paracetamol (=acetaminophen) for more than 28 days 
during fetal life had poorer gross motor development, 
communications skills and more externalizing prob-
lems compared to their unexposed siblings (21). The 
effect size was approximately one quarter of a standard 
deviation (e.g. β 0.24) which is of similar magnitude to 
the negative effect on cognitive and neurodevelopment 
seen in children exposed to lead in utero (22,23). This 
is to be considered a substantial effect especially after 
controlling for shared familial and genetic factors in 
the sibling design. Moreover, our effect estimates 
should be reconsidered in light of the public health 
perspective where a shift in the population central 
tendency of 0.24 standard deviation will result in a 
much larger proportion of the population above critical 
levels of behavioral problems (24) e.g. estimated from 
6% to 10% for behavioral disorders in our study. 
 At the same time, results from the Danish National 
Birth Cohort (DNBC) were published linking prenatal 
exposure to paracetamol to ADHD in children (25). In 
this birth cohort, children exposed to paracetamol in 
utero were more likely to have a hyperkinetic diagnosis 
(hazard ratio (HR) 1.37; 95% CI 1.19–1.59), to be 
using ADHD medications (HR 1.29; 95% CI 1.15–
1.44), or having ADHD-like behaviors at age 7 years 
(risk ratio 1.13; 95% CI 1.01–1.27). The authors state 
that the results did not appear to be confounded by 
potential confounders like maternal inflammation, 
infection during pregnancy and the mother's mental 
health problems, and stronger associations were ob-
served with increasing paracetamol exposures. 
 Because use of paracetamol is frequent in pregnan-
cy, these two Nordic cohort studies have caused con-
cern about neurodevelopmental side effects at the level 
of the European Medicines Agency (18), and been 
debated by the scientific community (26-30). Most 
recently, Damkier et al. question the use of psycho-
metric instruments such as the Ages and Stages Ques-
tionnaire (ASQ) to assess infant neurodevelopment 
(27). In our reply, we point out that we also used other 
measures in MoBa such as the Child Behaviour 
Checklist and the Emotionality, Activity and Shyness 
Temperament Questionnaire (EAS) in addition to a 
psychomotor milestone (age when the child started 
walking) (5). In the field of child psychology these are 
well-know and internationally recognized measure-
ments used clinically to assess child neurodevelop-
ment, but they may be less well-known and accepted 
by pharmacologists. 
 Similar findings have recently been published based 
on data from a New Zealand birth cohort in which pre-
natal exposure to paracetamol was associated with a 
significantly higher total difficulty scores (0.25 stan-
dard deviation, Strengths and Difficulty Questionnaire) 
and more symptoms of the DSM-IV hyperactive-
impulsive ADHD subtype at 7 years of age (31). The 
authors conclude that their findings strengthen the con-
tention that prenatal exposure to paracetamol increases 
the risk of ADHD-like behaviour in childhood. 
 Moreover, a Swedish animal study just recently con-
tributed with biological data by showing that exposure 
to repeated doses of paracetamol (30 + 30 mg/kg body-
weight) in mice induced altered locomotor activity and 
failure to acquire spatial learning in adulthood with 
observed changes in key brain regions (32). 
 MoBa data have been used in three other studies to 
assessed long-term neurodevelopmental outcomes after 
exposure to antidepressants (33) and antiepileptics, 
respectively (34,35). In the first study, one of the most 
important findings was the association between long-
term in utero exposure to SSRI-antidepressants 
(n=161) and language delay at three years of age 
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(adjusted relative risk ratios 2.30, 95% CI 1.21–4.37). 
Symptoms of anxiety and depression in pregnancy, 
however, were also associated with language delay in 
offspring, indicating an impact of the underlying ma-
ternal psychiatric illness (adjusted relative risk ratios 
1.83, 95% CI 1.40–2.40). A recent review of the litera-
ture on neurobehavioral outcome of infants exposed in 
utero concluded that both antidepressant medications 
and the underlying illness in itself may have negative 
impact on the developing fetus and that decisions 
regarding treatment of depression during pregnancy 
must be made on an individual basis (36). 
 It is well known that certain antiepileptics may in-
crease the risk of malformations, and some antiepilep-
tics (i.e. valproic acid) may possibly also have an in-
dependent negative impact on fetal cognitive develop-
ment (13). In a first study, a total of 333 MoBa children 
were exposed to valproate, lamotrigine, carbamazepine, 
or multiple antiepileptic drugs in utero. At three years 
of age, the exposed children had increased risk of 
gross motor delay (7.5% vs. 3.3%; OR 2.2, CI 1.1–4.2), 
poor sentence skills (11.2% vs. 4.8%; OR 2.1, CI 1.2–
3.6), and autistic traits (6.0% vs. 1.5%; OR 3.4, CI 
1.6–7.0). Confounding by the underlying epileptic 
illness could not explain the findings as children born 
to women with epilepsy who did not use antiepileptic 
drugs had no increased risks and children of fathers 
with epilepsy generally scored within the normal range 
(34). In the second study, the impact of breast feeding, 
while using antiepileptics, on infant neurodevelopment 
was specifically assessed, but no harmful effects of 
breastfeeding was detected (35). The authors conclu-
ded that women with epilepsy should be encouraged to 
breastfeed their children irrespective of antiepileptic 
drug treatment, which is in line with the current litera-
ture (13). 
 
Herbal remedies  
In parallel to medication safety studies, we have been 
working with the use of herbal remedies in pregnancy 
(37-40). To our surprise, we found that up to 40% of 
Norwegian women were using herbal remedies during 
pregnancy (38,40), despite a lack of data on efficacy 
and safety in pregnancy for most of these herbs. As the 
MoBa study includes questions about herbal remedies 
during pregnancy, this offered an opportunity to study 
consequences of such use. 
 In two MoBa sub-studies (n=68,522 women), the 
safety of the two most frequently used herbals during 
pregnancy were investigated, namely ginger (41) and 
cranberry (42). In general, very little information exists 
on these herbal preparations despite their widespread 
use. 
 In the first study, 1,020 (1.5%) women reported 
using ginger (most commonly against nausea) during 
pregnancy (41). The use of ginger during pregnancy 
was not associated with any increased risk of con-
genital malformation (adjusted OR 0.8, 95% CI 0.5–
1.4) or with any of the other pregnancy outcomes 
investigated (i.e. preterm birth and low birth weight, 
adjusted risk estimates ranging from 0.7 to 1.0) com-
pared to women who had not been exposed (41). 
 In the second study, 919 (1.3%) women reported 
using cranberry during pregnancy, most commonly in 
relation to urinary tract infections (UTI) (42). No in-
creased risk of major congenital malformations (adjus-
ted OR 0.7, 95% CI 0.4–1.3) or any other negative 
pregnancy outcomes investigated after use of cranberry 
were identified in analyses adjusting for confounding 
factors (adjusted risk estimates ranging from 0.7 to 
1.1). Stratified analyses according to use/no use of 
antibiotics for UTI were performed to investigate 
whether UTI without conventional therapy could 
increase the risk of negative pregnancy outcomes. No 
such effect was found, but study power in these sub-
analyses were in most cases too low to conclude (42). 
 
Other MoBa studies on medication safety  
Risk of oral clefts after exposure to topical cortico-
steroids was assessed in one case control study using 
data from both the MoBa and The Norway Cleft Study 
(43). No increased risk of oral clefts was detected in 




RELEVANT TO MEDICATION SAFETY STUDIES 
IN MOBA 
 
Pharmaco-epidemiological studies are vital to our un-
derstanding of the safety of medications in pregnancy, 
but great care must be taken in the analysis and 
interpretation of observational data. Over the last fifty 
years, there have been several cases in which widely 
used drugs were falsely labelled as human teratogens 
due to signals in pharmaco-epidemiological studies 
(44), causing women to terminate otherwise-wanted 
pregnancies, and inducing tremendous levels of anxiety 
among women and their families. These included the 
antiemetic Bendectin (pyridoxine/doxylamine) (45) 
and the antihistamine loratadine (46) to mention a few. 
 Common methodological challenges in medication 
safety studies in pregnancy are sample size (e.g., 
power), errors in measurement of medication use, and 
bias in the form of selection bias, information bias and 
confounding. Sources of errors or bias should be 
acknowledged and discussed, and preferably quanti-
fied by performing sensitivity analysis of estimates 
under a range of assumption about bias direction and 
magnitude. 
 The main challenge in several of our MoBa studies 
focusing on malformations in offspring is that most 
malformations occur spontaneously at low rates (3-
4%), and most human teratogens increase such risk 
modestly. For example, in a cohort study one needs 
330 exposed cases and 8000 unexposed controls to 
show a two-fold increased risk for overall malforma-
tions, assuming a baseline prevalence rate of 3% and 
80% statistical power with an alpha value of 0.05. 
MEDICATION SAFETY IN PREGNANCY – RESULTS FROM THE MOBA STUDY 165 
 
When dealing with specific malformations, the abso-
lute rates are much lower. For example, cardiac defects 
occur in approximately 1% of the population. To 
exclude a doubling of risk with 80% statistical power 
with an alpha value of 0.05, 1200 exposed cases and 
8000 controls are necessary. A way to increase the 
statistical power of relatively small cohort studies of 
similar design is to synthesize them into a meta-
analysis. 
 The accuracy of medication exposure in MoBa 
depends on the accuracy of maternal recall. Previous 
validation studies indicate that completeness of 
reported medication use in pregnancy depends on the 
type of medication of interest and on the specificity of 
the questions asked, with structured questions about 
indications being more accurate than open-ended 
questions; i.e., “Have you used any medications in 
pregnancy?” and “If yes, which?” (47,48). Also, the 
woman’s ability to remember accurately declines as 
the length of time between the time when the drug was 
taken and the interview increases. Medications that are 
taken daily in pregnancy, such as insulin are more 
accurately reported than short term therapies such as 
antibiotic eye drops and decongestant nose sprays. 
 In MoBa, we had the advantage that the women had 
the opportunity to report medication use for 77 diffe-
rent indications during pregnancy. However, due to the 
limited space provided in the questionnaires under 
each indication, underreporting of medication use may 
occur. This fact, and the low participation rate in 
MoBa, implies that the prevalence of medication use 
in pregnancy, most likely, will not be representative 
for the Norwegian pregnant population at large. Asso-
ciations between medication exposures and pregnancy 
outcomes, however, are assumed to be more robust. As 
MoBa data is collected prospectively before the preg-
nancy outcome is known, this would most likely result 
in a non-differential exposure misclassification and 
bias of the effect estimates towards 1.0. One potential 
source of misclassification occurred when several 
medications were reported and several check boxes for 
timing of use in pregnancy were crossed out. In such 
cases, we assumed that these women were exposed to 
all medications reported in all time periods selected. 
To determine whether our decision influenced the 
results of our analyses, we performed sensitivity 
analyses on different exposure scenarios. In addition, 
in MoBa, no questions were asked about dosage, and 
information about the duration of medication use was 
missing for several women. 
 A major challenge in observational drug safety stu-
dies is the interpretation of causal effects. Often, con-
founding by indication, socio-economic factors or life 
style habits cannot be ruled out. Inclusion of a disease 
comparison group and comparisons of medication 
effects across indications and across mechanisms of 
action, are two important approaches that are possible 
in MoBa, since information about indication, and in 
some cases, information about severity is included (i.e. 
symptoms of depression measured by the Symptoms 
Check List-5 and -8). Similar associations across diffe-
rent indications and among medications with similar 
modes of action increase the possibility of a causal 
association. 
 The possibility that associations are due to genetic 
or family environmental risks rather than antidepress-
ant use, per se, cannot easily be ruled out in conventio-
nal studies. In several of our MoBa studies we are now 
evaluating the association between prenatal medication 
exposure and problems in offspring using a sibling 
control design. The sibling control design may provide 
one of the most effective approaches to control for 
family factors when large epidemiological cohorts and 
sufficient discordant siblings are available (49). This 
sibling-control design is suitable because siblings share 
familial environment (e.g. maternal chronic disease) 
and 50% of their genetic predisposition, while they 
may differ on medication exposure during pregnancy. 
 
 
CRITERIA FOR TERATOGENICITY 
 
A teratogenic effect could result in several outcomes 
that are important for establishing the safety of medi-
cations in pregnancy. These include congenital malfor-
mations, spontaneous abortions, stillbirth, low birth 
weight, and long-term neurodevelopmental delays and 
disorders. 
 The following six criteria are often used to establish 
whether a medication is teratogenic (50): 1. The drug 
should pass the placenta, 2. There should be a biolo-
gical plausible explanation for the finding (mechanism 
of teratogenicity), 3. There should be a relevant tem-
poral relationship between exposure and outcome. The 
exposure to the medication has to have taken place at a 
vulnerable time in fetal development (for example, a 
medication cannot cause a neural tube defect after the 
neural tube has closed), 4. Specificity is important as 
most teratogens will produce a certain type of malfor-
mation. A specific syndrome increases the likelihood 
of causation (for example, if anotia (lack of ears) 
occurs spontaneously in 1:20 000 births, and three 
successive cases of exposure to isotretinoin result in 
infants born without ears, then this medication is most 
likely a human teratogen), 5. Replication is important, 
and should be consistent in at least two or more high-
quality pharmaco-epidemiological studies, and 6. 
Support from animal experiments. Teratogenicity in 
animals can give important information, but is not 
essential as results from animal studies cannot auto-
matically be extrapolated to humans. The doses used 
in animal studies are often ten- to hundredfold in 
excess of human therapeutic doses. 
 
 
FUTURE RESEARCH POSSIBILITIES IN MOBA 
 
There are three especially relevant research possibili-
ties for medication safety studies in MoBa. Firstly, it is 
becoming increasingly clear to scientists, clinicians and 
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the public alike that the reproductive safety of medica-
tions cannot be assured without considering potential 
long-term consequences on the developing brain. Dis-
ruptions during fetal neurodevelopment may lead to 
psychomotor, temperamental and behavioral disabili-
ties. The etiology of many neurodevelopmental dis-
orders, including ADHD, is still poorly understood, but 
may include exposure to medications in the prenatal 
period. The nature of MoBa with a broad range of 
neurodevelopmental measures and follow-up into ado-
lescence and onward, will allow for these studies, and 
thus offers to fill an important knowledge gap on long-
term medication safety. 
 Secondly, another recently emerging field in which 
MoBa and the biobank can potentially play a leading 
role is in the field of human pharmaco-epigenetics. 
Human studies showing alterations in DNA methylation 
patterns after in utero exposure to medications have just 
started to emerge, with links to neurobehavioral dis-
orders (51-55). These sparse human findings must be 
replicated. If proven correct, the consequences for 
modern medicine will be profound, since it would imply 
that our current understanding of pharmacology is an 
oversimplification. 
 Thirdly, collaboration with other birth cohorts in 
Europe and North America is promising. Collaboration 
will not only allow replication of findings, but also the 
pooling of data to investigate less frequently used 
medications and rare outcomes that neither of the birth 
cohorts would have adequate study power to examine 
alone. Moreover, linkage of MoBa to other nationwide 
registries like the Norwegian Prescription Database 
(NorPD), and to the National Patient Registry will 
allow for validation of exposure to prescribed medica-
tions and inclusion of a medically confirmed diagnosis 
in addition to self-reported diseases and psychometric 
measurements, respectively. Advanced statistical tech-
niques will enable us to control complex, intertwined 
time-varying exposures and confounding factors to 
obtain estimates of effects that are less biased than 
traditional regression methods, thereby giving us 
greater confidence in the validity of our findings. 
 
CONCLUSION  
In practice, pharmacoepidemiological studies provide 
the best way of evaluating whether an exposure during 
pregnancy has adverse effects on the developing fetus. 
The Norwegian Mother and Child Cohort Study has 
already enabled several medication safety studies in 
pregnancy, providing reassuring results for antidepres-
sants and supporting current guidelines of avoiding 
NSAIDs during the first and third trimester. A new 
signal of behavioral problems after long-term use of 
paracetamol was detected using a sibling-design. To-
gether with the MoBa biobank, and through linkage to 
other nationwide registries, the MoBa study will 
continue to be an extremely valuable data source for 
medication safety studies in pregnancy in the future. 
The knowledge generated from these studies will not 
only benefit pregnant women in Norway, but women, 
their children and families worldwide. 
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